Emily J. Hanan

发表

Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.

Jane R Kenny, Michael Siu, Deepak Sampath, 2012, Journal of medicinal chemistry.

Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.

Adam R. Johnson, N. C. Ray, Rohan V Mendonca, 2019, Bioorganic & medicinal chemistry letters.

Abstract A20: Development and validation of a novel acute myeloid leukemia xenograft model that is dependent on the JAK2V617F mutation for growth in vivo

Leslie B. Lee, Christine Chang, D. Sampath, 2009 .

Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists.

M. Arkin, S. Prabhu, W. Shen, 2011, Bioorganic & medicinal chemistry letters.

Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists.

M. Arkin, K. Huen, B. Cunningham, 2010, Bioorganic & medicinal chemistry letters.

Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR.

C. Eigenbrot, Ivana Yen, S. Sideris, 2016, ACS medicinal chemistry letters.

2-Aminobenzimidazoles as potent Aurora kinase inhibitors.

Amy D. Fung, T. O'Brien, W. Flanagan, 2009, Bioorganic & medicinal chemistry letters.

Structure of the essential inner membrane lipopolysaccharide–PbgA complex

Benjamin D. Sellers, M. Hunter, D. DePonte, 2020, Nature.

Deletion of a previously uncharacterized lipoprotein lirL confers resistance to an inhibitor of type II signal peptidase in Acinetobacter baumannii

W. Sandoval, D. Yan, Min Xu, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Optimization of globomycin analogs as novel gram-negative antibiotics.

S. Gloor, Min Xu, Richard M Pastor, 2020, Bioorganic & medicinal chemistry letters.

Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.

M. Arkin, S. Prabhu, W. Shen, 2012, ACS medicinal chemistry letters.

Mild and General One-Pot Reductionand Cyclization of Aromatic and Heteroaromatic 2-Nitroaminesto Bicyclic 2H-Imidazoles

J. Lyssikatos, B. Chan, Anthony A. Estrada, 2010 .

4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase.

C. Eigenbrot, Ivana Yen, S. Sideris, 2016, Bioorganic & medicinal chemistry letters.

Unstable Mechanisms of Resistance to Inhibitors of Escherichia coli Lipoprotein Signal Peptidase

Z. Modrušan, L. Komuves, S. Gloor, 2020, mBio.

Discovery of a potent and selective aurora kinase inhibitor.

Wang Shen, Amy D. Fung, Joni W. Lam, 2008, Bioorganic & medicinal chemistry letters.

Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.

Siew K. Yeap, M. Ultsch, C. Eigenbrot, 2022, Journal of medicinal chemistry.

RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy

W. Forrest, Kyung Song, L. Friedman, 2021, bioRxiv.

Monomeric targeted protein degraders.

Jun Liang, R. Blake, N. Blaquière, 2020, Journal of medicinal chemistry.

Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor.

Siew K. Yeap, C. Eigenbrot, Ivana Yen, 2016, Journal of medicinal chemistry.

Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.

Belen Dominguez-Fernandez, C. Eigenbrot, Ivana Yen, 2015, Journal of medicinal chemistry.

Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation

Siew K. Yeap, C. Eigenbrot, Ivana Yen, 2014, Journal of medicinal chemistry.

Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.

R. Fucini, I. C. Choong, Joshua C. Yoburn, 2008, Bioorganic & medicinal chemistry letters.

Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.

Jane R Kenny, Philippe Bergeron, Tian Jin, 2012, Journal of medicinal chemistry.

Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors.

R. Fucini, R. Elling, W. Lew, 2008, Bioorganic & medicinal chemistry letters.

Abstract 156: Preclinical characterization of GDC-0077, a specific PI3K alpha inhibitor in early clinical development

M. Belvin, Kyung Song, L. Friedman, 2017 .

Structure of the Brachydanio rerio Polo-like kinase 1 (Plk1) catalytic domain in complex with an extended inhibitor targeting the adaptive pocket of the enzyme.

R. Fucini, K. Paulvannan, R. Elling, 2008, Acta crystallographica. Section F, Structural biology and crystallization communications.